Report

Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1

See allHide authors and affiliations

Science  09 Jan 2015:
Vol. 347, Issue 6218, pp. 188-194
DOI: 10.1126/science.1257132

Sensing amino acids at the lysosome

The mTORC1 protein kinase is a complex of proteins that functions to regulate growth and metabolism. Activity of mTORC1 is sensitive to the abundance of amino acids, but how the sensing of amino acids is coupled to the control of mTORC1 has been unclear. Wang et al. searched for predicted membrane proteins that interacted with regulators of mTORC1. They identified a protein currently known only as SLC38A9. Interaction of SLC38A9 with mTORC1 regulators was sensitive to the presence of amino acids. SLC38A9 has sequence similarity to amino acid transporters. Effects of modulation of SLC38A9 in cultured human cells indicate that it may be the sensor that connects the abundance of arginine and leucine to mTORC1 activity.

Science, this issue p. 188

Abstract

The mechanistic target of rapamycin complex 1 (mTORC1) protein kinase is a master growth regulator that responds to multiple environmental cues. Amino acids stimulate, in a Rag-, Ragulator-, and vacuolar adenosine triphosphatase–dependent fashion, the translocation of mTORC1 to the lysosomal surface, where it interacts with its activator Rheb. Here, we identify SLC38A9, an uncharacterized protein with sequence similarity to amino acid transporters, as a lysosomal transmembrane protein that interacts with the Rag guanosine triphosphatases (GTPases) and Ragulator in an amino acid–sensitive fashion. SLC38A9 transports arginine with a high Michaelis constant, and loss of SLC38A9 represses mTORC1 activation by amino acids, particularly arginine. Overexpression of SLC38A9 or just its Ragulator-binding domain makes mTORC1 signaling insensitive to amino acid starvation but not to Rag activity. Thus, SLC38A9 functions upstream of the Rag GTPases and is an excellent candidate for being an arginine sensor for the mTORC1 pathway.

The mechanistic target of rapamycin complex 1 (mTORC1) protein kinase is a central controller of growth that responds to the nutritional status of the organism and is deregulated in several diseases, including cancer (13). Upon activation, mTORC1 promotes anabolic processes, including protein and lipid synthesis, and inhibits catabolic ones, such as autophagy (4). Environmental cues such as nutrients and growth factors regulate mTORC1, but how it senses and integrates these diverse inputs is unclear.

The Rag and Rheb guanosine triphosphatases (GTPases) have essential but distinct roles in mTORC1 pathway activation, with the Rags controlling the subcellular localization of mTORC1 and Rheb stimulating its kinase activity (5). Nutrients, particularly amino acids, activate the Rag GTPases, which then recruit mTORC1 to the lysosomal surface, where they are concentrated (6, 7). Rheb also localizes to the lysosomal surface (6, 810) and, upon growth factor withdrawal, the tuberous sclerosis complex (TSC) tumor suppressor translocates there and inhibits mTORC1 by promoting guanosine 5′-triphosphate (GTP) hydrolysis by Rheb (10). Thus, the Rag and Rheb inputs converge at the lysosome, forming two halves of a coincidence detector that ensures that mTORC1 activation occurs only when both are active.

There are four Rag GTPases in mammals and they form stable, obligate heterodimers consisting of RagA or RagB with RagC or RagD. RagA and RagB are highly similar and functionally redundant, as are RagC and RagD (1, 6). The function of each Rag within the heterodimer is poorly understood, and their regulation is likely complex, as many distinct factors play important roles. A lysosome-associated molecular machine containing the multisubunit Ragulator and vacuolar adenosine triphosphatase (v-ATPase) complexes regulates the Rag GTPases and is necessary for mTORC1 activation by amino acids (11). Ragulator anchors the Rag GTPases to the lysosome and also has nucleotide exchange activity for RagA/B (12, 13), but the molecular function of the v-ATPase in the pathway is unknown. Two GTPase-activating protein (GAP) complexes, which are both tumor suppressors, promote GTP hydrolysis by the Rag GTPases, with GATOR1 acting on RagA/B (14) and Folliculin-FNIP1/2 on RagC/D (15). Last, a distinct complex called GATOR2 negatively regulates GATOR1 through an unknown mechanism (14). Despite the identification of many proteins involved in signaling amino acid sufficiency to mTORC1, the actual amino acid sensors remain unknown.

We have proposed that amino acid sensing initiates at the lysosome and requires the presence of amino acids in the lysosomal lumen (11). Thus, we sought to identify, as candidate sensors, proteins that interact with known components of the pathway and also have transmembrane domains. Mass spectrometric analyses of nonheated immunoprecipitates of several Ragulator components and, to a lesser extent, RagB revealed the presence of isoform 1 of SLC38A9 (SLC38A9.1), a previously unstudied protein with sequence similarity to the SLC38 class of sodium-coupled amino acid transporters (16) (Fig. 1A). SLC38A9.1 is predicted to have 11 transmembrane domains, a cytosolic N-terminal region of 119 amino acids, and three N-linked glycosylation sites in the luminal loop between transmembrane domains 3 and 4 (Fig. 1B and fig. S1, A and B). When stably expressed in human embryonic kidney–293T (HEK-293T) cells, SLC38A9.1 migrated on SDS–polyacrylamide gel electrophoresis as a smear that collapsed to near its predicted molecular mass of 63.8 kD after treatment with peptide N-glycosidase F (PNGase F) (Fig. 1C). Isoforms 2 (SLC38A9.2) and 4 (SLC38A9.4) lack the first 63 or 124 amino acids of SLC38A9.1, respectively (Fig. 1B).

Fig. 1 Interaction of SLC38A9.1 with Ragulator and the Rag GTPases.

(A) The spectral counts of SLC38A9-derived peptides detected by mass spectrometry in immunoprecipitates prepared from HEK-293T cells stably expressing the indicated FLAG-tagged proteins. (B) Schematic depicting SLC38A9 isoforms and truncation mutants. Transmembrane domains predicted by the TMHMM (transmembrane hidden Markov model) algorithm (http://www.cbs.dtu.dk/services/TMHMM/) are shown as blue boxes. (C) Effects of PNGase F treatment of SLC38A9.1 on its electrophoretic migration. (D) Interaction of full-length SLC38A9.1 or its N-terminal domain with endogenous Ragulator (p18 and p14) and RagA and RagC GTPases. HEK-293T cells were transfected with the indicated cDNAs in expression vectors, and lysates were prepared and subjected to FLAG immunoprecipitation followed by immunoblotting for the indicated proteins. (E) Identification of key residues in the N-terminal domain of SLC38A9.1 required for it to interact with Ragulator and the Rag GTPases. Experiment was performed as in (D) using indicated SLC38A9.1 mutants. (F) Interaction of SLC38A9.1 with v-ATPase components V0d1 and V1B2. HEK-293T cells stably expressing the indicated FLAG-tagged proteins were lysed and processed as in (D).

As expected from the mass spectrometry results, immunoprecipitates of stably expressed FLAG-tagged SLC38A9.1, but not of three other lysosomal membrane proteins—LAMP1 (17), SLC36A1 (18), and SLC38A7 (19)—contained Ragulator (as detected by its p14 and p18 components), RagA, and RagC (Fig. 1D and fig. S2A). Indicative of the strength of the Ragulator-SLC38A9.1 interaction, the amounts of endogenous Ragulator that coimmunoprecipitated with SLC38A9.1 were similar to those associated with the RagB-RagC heterodimer (Fig. 1D). In contrast, SLC38A9.2, SLC38A9.4, or a mutant of SLC38A9.1 lacking its first 110 amino acids (SLC38A9.1 Δ110) did not associate with Ragulator (fig. S2, B and C). The N-terminal region of SLC38A9.1 is sufficient for it to interact with Ragulator-Rag because on its own, the first 119 amino acids of SLC38A9.1 coimmunoprecipitated similar amounts of Ragulator and Rag GTPases, as did the full-length protein (Fig. 1D and fig. S2C). Using alanine scanning mutagenesis of residues in the N-terminal region conserved to the SLC38A9.1 homolog in Caenorhabditis elegans (F13H10.3), we identified I68, Y71, L74, P85, and P90 as required for the Ragulator-SLC38A9.1 interaction (Fig. 1E).

The v-ATPase and its activity are necessary for amino acid sensing by the mTORC1 pathway, and, like SLC38A9.1, it coimmunoprecipitated with stably expressed FLAG-tagged Ragulator (11, 20, 21). Indicating the existence of a supercomplex, stably expressed SLC38A9.1, but not LAMP1, associated with endogenous components of the v-ATPase in addition to Ragulator and the Rag GTPases (Fig. 1F). Although SLC38A9.2 does not interact with Ragulator, it did coimmunoprecipitate the v-ATPase, albeit at lesser amounts than SLC38A9.1 (Fig. 1F). This suggests that the interaction between SLC38A9.1 and the v-ATPase is mediated not through Ragulator but directly or indirectly through the region of SLC38A9.1 that contains its transmembrane domains. Concordant with this interpretation, the N-terminal domain of SLC38A9.1, which interacts strongly with Ragulator, did not coimmunoprecipitate the v-ATPase (Fig. 1F).

Well-characterized members of the SLC38 family of amino acid transporters (SLC38A1-5) localize to the plasma membrane (22), but at least one member, SLC38A7, is a lysosomal membrane protein (19). This is also the case for SLC38A9.1, SLC38A9.2, and SLC38A9.4 because in HEK-293T cells, all three isoforms colocalized with LAMP2, an established lysosomal membrane protein (Fig. 2A and fig. S3, A and B). Amino acids did not affect the lysosomal localization of SLC38A9.1 (Fig. 2A). As would be expected if SLC38A9.1 binds to Ragulator at the lysosome, a Ragulator mutant that does not localize to the lysosomal surface, because its p18 component lacks lipidation sites (23), did not interact with SLC38A9.1 (fig. S3C).

Fig. 2 Localization of SLC38A9.1 to the lysosomal membrane in an amino acid–independent fashion and requirement of SLC38A9 for mTORC1 pathway activation by amino acids.

(A) SLC38A9.1 localization in cells deprived of or replete with amino acids. HEK-293T cells stably expressing FLAG-SLC38A9.1 were starved and stimulated with amino acids for the indicated times. Cells were processed and immunostained for LAMP2 and FLAG-SLC38A9.1. (B) Requirement of SLC38A9 for the activation of the mTORC1 pathway by amino acids. HEK-293T cells expressing indicated short hairpin RNAs (shRNAs) were deprived of amino acids for 50 min or deprived of and then restimulated with amino acids for 10 min. Cell lysates were analyzed for the levels of indicated proteins and the S6K1 phosphorylation state.

Short hairpin RNA (shRNA)—or small interfering RNA (siRNA)—mediated depletion of SLC38A9 in HEK-293T cells suppressed activation of mTORC1 by amino acids, as detected by the phosphorylation of its established substrate ribosomal protein S6 kinase 1 (S6K1) (Fig. 2B and fig. S3D). Thus, like the five known subunits of Ragulator (12, 13), SLC38A9.1 is a positive component of the mTORC1 pathway. We conclude that SLC38A9.1 is a lysosomal membrane protein that interacts with Ragulator and the Rag GTPases through its N-terminal 119 amino acids (“Ragulator-binding domain”) and is required for mTORC1 activation.

Given the similarity of SLC38A9.1 to amino acid transporters, we reasoned that it might act in conveying amino acid sufficiency to Ragulator and the Rag GTPases. Indeed, stable or transient overexpression in HEK-293T cells of SLC38A9.1, but not of several control proteins, rendered mTORC1 signaling resistant to total amino acid starvation or to just that of leucine or arginine, two amino acids that regulate mTORC1 activity in many cell types (2426) (Fig. 3A and fig. S4A). Overexpression of SLC38A9.1 did not affect the regulation of mTORC1 by growth factor signaling (fig. S4, D and E). Commensurate with its effects on mTORC1, SLC38A9.1 overexpression suppressed the induction of autophagy caused by amino acid starvation (fig. S4C), a phenotype shared with activated alleles of RagA and RagB (6, 7, 27). Overexpression of variants of SLC38A9 that do not interact with Ragulator and the Rag GTPases, including SLC38A9.2, SLC38A9.4, and the SLC38A9.1 Δ110 and SLC38A9.1 I68A mutants, failed to maintain mTORC1 signaling after amino acid withdrawal (Fig. 3, B and C, and fig. S4A). Thus, even in cells deprived of amino acids, some of the overexpressed SLC38A9.1 protein appears to be in an active conformation that confers amino acid insensitivity on mTORC1 signaling in a manner dependent on its capacity to bind Ragulator and Rags. SLC38A9.1 overexpression also activated mTORC1 in the absence of amino acids in HEK-293E, HeLa, and LN229 cells, as well as in mouse embryonic fibroblasts (MEFs), with the degree of activation proportionate to the amount of SLC38A9.1 expressed (fig. S4B). Overexpression of just the Ragulator-binding domain of SLC38A9.1 mimicked the effects of the full-length protein on mTORC1 signaling (Fig. 3D), which indicated that it can adopt an active state when separated from the transmembrane portion of SLC38A9.1.

Fig. 3 Stable overexpression of full-length SLC38A9.1 or its N-terminal Ragulator-binding domain makes the mTORC1 pathway insensitive to amino acid deprivation.

(A) Stable overexpression of FLAG-SLC38A9.1 largely restores mTORC1 signaling during total amino acid starvation and completely restores it upon deprivation of leucine or arginine. HEK-293T cells transduced with lentiviruses encoding the specified proteins were deprived for 50 min of all amino acids, leucine, or arginine and, where indicated, restimulated for 10 min with the missing amino acid(s). Cell lysates were analyzed for the levels of the specified proteins and the phosphorylation states of S6K1, ULK1, and 4E-BP1. (B and C) Overexpression of neither SLC38A9.2 nor a point mutant of SLC38A9.1 that fails to bind Ragulator rescues mTORC1 signaling during amino acid starvation. Experiment was performed as in (A) except that cells were stably expressing SLC38A9.2 (B) or SLC38A9.1 I68A (C). (D) Stable overexpression of the Ragulator-binding domain of SLC38A9.1 largely restores mTORC1 signaling during total amino acid starvation and completely rescues it upon deprivation of leucine or arginine. Experiment was performed as in (A) except that cells were stably expressing FLAG-SLC38A9.1 1-119. (E) The ability of SLC38A9.1 overexpression to rescue mTORC1 signaling during amino acid starvation is eliminated by coexpression of RagBT54N-RagCQ120L, a Rag heterodimer locked in the nucleotide configuration associated with amino acid deprivation. Effects of expressing the indicated proteins on mTORC1 signaling were monitored by the phosphorylation state of coexpressed FLAG-S6K1. (F) Effects of concanamycin A and Torin1 on mTORC1 signaling in cells stably expressing SLC38A9.1. HEK-293T cells stably expressing the indicated FLAG-tagged proteins were treated with the dimethyl sulfoxide (DMSO) vehicle or the specified small-molecule inhibitor during the 50-min starvation for and, where indicated, the 10-min stimulation with amino acids.

The gain-of-function phenotype caused by SLC38A9.1 overexpression offered an opportunity to test its relation to the Rag GTPases, mTORC1, and the v-ATPase. The Rag GTPases and mTORC1 both function downstream of SLC38A9.1, as expression of the dominant-negative Rag heterodimer (RagBT54N-RagCQ120L) or treatment with the mTOR inhibitor Torin1 (28) completely inhibited mTORC1 activity, whether SLC38A9.1 was overexpressed or not (Fig. 3, E and F). In contrast, the v-ATPase has a more complex relationship with SLC38A9.1. Its inhibition with concanamycin A eliminated mTORC1 signaling in the control cells but only partially blocked it in cells overexpressing SLC38A9.1 (Fig. 3F). These results suggest a model in which SLC38A9.1 and the v-ATPase represent parallel pathways that converge upon the Ragulator-Rag GTPase complex.

Amino acids modulate the interactions between many of the established components of the amino acid sensing pathway, so we tested if this was also the case for the SLC38A9.1-Ragulator-Rag complex. Indeed, amino acid starvation strengthened the interaction between stably expressed or endogenous Ragulator and endogenous SLC38A9 (Fig. 4A and fig. S5), as well as between stably expressed SLC38A9.1 and endogenous Ragulator and Rags (Fig. 4B). We obtained similar results when cells were deprived of and stimulated with just leucine or arginine (Fig. 4A). Curiously, although the N-terminal domain of SLC38A9.1 readily bound Ragulator, the interaction was insensitive to amino acids (Fig. 4B), which suggested that the transmembrane region is required to confer amino acid responsiveness.

Fig. 4 Modulation of the interaction between SLC38A9 and Ragulator and the Rag GTPases by amino acids.

(A) Effects of amino acids on interaction between the Ragulator complex and endogenous SLC38A9. HEK-293T cells stably expressing the indicated FLAG-tagged Ragulator components were deprived of total amino acids (AA), leucine (L), or arginine (R) for 1 hour and, where indicated, restimulated with amino acids, leucine, or arginine for 15 min. After lysis, samples were subject to FLAG immunoprecipitation and immunoblotting for the indicated proteins. Quantification of SLC38A9 levels in the stimulated state relative to starved state, p14 IP: 0.75 (+AA), 0.79 (+L), 0.74 (+R); p18 IP: 0.56 (+AA), 0.57 (+L), 0.49 (+R). (B) Effects of amino acids on the interaction between full-length or truncated SLC38A9.1 and endogenous Ragulator and the Rag GTPases. Experiment was performed as in (A) except that cells stably expressed the indicated SLC38A9 isoforms or its N-terminal domain (SLC38A9.1 1-119). Quantification of indicated protein levels in the stimulated state relative to starved state, SLC38A9.1 IP: 0.43 (p18), 0.51 (p14), 0.61 (RagC), 0.58 (RagA); SLC38A9.1 1-119 IP: 0.99 (p18), 1.05 (p14), 1.04 (RagC), 1.09 (RagA). (C) Effects of nucleotide-binding mutations in the Rag GTPases on association with endogenous SLC38A9. HEK-293T cells were transfected with the indicated cDNAs in expression vectors, and lysates were prepared and subjected to FLAG immunoprecipitation followed by immunoblotting for the indicated proteins. Two different antibodies were used to detect endogenous SLC38A9.

As amino acid starvation alters the nucleotide state of the Rag GTPases (6, 7), we tested whether SLC38A9 interacted differentially with mutants of the Rags that lock their nucleotide state. Heterodimers of epitope-tagged RagB-RagC containing RagBT54N, which mimics the GDP-bound state (6, 7), were associated with more endogenous SLC38A9 than were heterodimers containing wild-type RagB (Fig. 4C). In contrast, heterodimers containing RagBQ99L, which lacks GTPase activity and so is bound to GTP (6, 7, 15), interacted very weakly with SLC38A9 (Fig. 4C). Thus, like Ragulator, SLC38A9 interacts most readily with Rag heterodimers in which RagA/B is GDP-loaded, which is consistent with SLC38A9 binding to Ragulator and with Ragulator being a guanine nucleotide exchange factor (GEF) for RagA/B. These results suggest that amino acid modulation of the interaction of SLC38A9.1 with Rag-Ragulator largely reflects amino acid–induced changes in the nucleotide state of the Rag GTPases. Because the RagB mutations had greater effects on the interaction of the Rag GTPases with SLC38A9 than with Ragulator (in Fig. 4C, compare the SLC38A9 blots with those for p14 and p18), it is very likely that the Rag heterodimers make Ragulator-independent contacts with SLC38A9 that affect the stability of Rag-SLC38A9 interaction.

We failed to detect SLC38A9.1-mediated amino acid transport or amino acid–induced sodium currents in live cells in which SLC38A9.1 was so highly overexpressed that some reached the plasma membrane (fig. S6, A to E). Because these experiments were confounded by the presence of endogenous transporters or relied on indirect measurements of transport, respectively, we reconstituted SLC38A9.1 into liposomes to directly assay the transport of radiolabeled amino acids. Affinity-purified SLC38A9.1 inserted unidirectionally into liposomes so that its N terminus faced outward in an orientation analogous to that of the native protein in lysosomes (fig. S6, F to H). We could not use radiolabeled l-leucine in transport assays because it bound nonspecifically to liposomes, so we focused on the transport of l-arginine, which had low background binding (fig. S6I). The SLC38A9.1-containing proteoliposomes exhibited time-dependent uptake of radiolabeled arginine, whereas those containing LAMP1 interacted with similar amounts of arginine as liposomes (Fig. 5A and fig. S6I). Steady-state kinetic experiments revealed that SLC38A9.1 has a Michaelis constant (Km) of ~39 mM and a catalytic rate constant (kcat) of ~1.8 min−1 (Fig. 5B), indicating that SLC38A9.1 is a low-affinity amino acid transporter. SLC38A9.1 can also efflux arginine from the proteoliposomes (Fig. 5C), but its orientation in liposomes makes it impossible to obtain accurate Km and kcat measurements for this activity. It is likely that by having to assay the transporter in the “backward” direction we are underestimating its affinity for amino acids during their export from lysosomes.

Fig. 5 SLC38A9.1 is a low-affinity amino acid transporter and is necessary for mTORC1 pathway activation by arginine.

(A) Time-dependent uptake of [3H]arginine at 0.5 μM by proteoliposomes containing 22.4 pmol of SLC38A9.1. To recapitulate the pH gradient across the lysosomal membrane, the lumen of the proteoliposomes is buffered at pH 5.0, whereas the external buffer is pH 7.4. (B) Steady-state kinetic analysis of SLC38A9.1 uptake activity reveals a Km of ~39 mM and kcat of ~1.8 min−1. (Left) Time course of [3H]arginine (R*) uptake, given fixed [3H]arginine (0.5 μM) and increasing concentrations of unlabeled arginine. (Right) Velocity, calculated from left panel, as a function of total arginine concentration. Data were fitted to the Michaelis-Menten equation. Experiment was repeated more than four times with similar results, and a representative one is shown. (C) Time-dependent efflux of SLC38A9.1 proteoliposomes after 1.5 hours loading with 0.5 μM [3H]arginine. (D) Competition of 0.5 μM [3H]arginine transport by SLC38A9.1 using 100 mM of indicated unlabeled amino acids. In (A) to (D), error bars represent standard deviation derived from at least three measurements. (E) HEK-293T cells null for SLC38A9 were generated by CRISPR-Cas9 genome editing with two different guide sequences and isolated by single-cell cloning. The AAVS1 locus was targeted as a negative control. (F) Impairment of arginine-induced activation of the mTORC1 pathway in SLC38A9-null HEK-293T cells. Cells were starved of the indicated amino acid for 50 min and stimulated for 10 min with the indicated amino acid concentrations. The leucine and arginine concentrations in RPMI are, respectively, 381 μM and 1.14 mM. (G) Model for distinct amino acid inputs to the Rag GTPases in signaling amino acid sufficiency to mTORC1.

To assess the substrate specificity of SLC38A9.1, we performed competition experiments using unlabeled amino acids (Fig. 5D). The positively charged amino acids histidine and lysine competed radiolabeled arginine transport to similar degrees as arginine, while leucine had a modest effect and glycine was the least effective competitor. Thus, it appears that SLC38A9.1 has a relatively nonspecific substrate profile with a preference for polar amino acids.

Given the preference of SLC38A9.1 for the transport of arginine and that arginine is highly concentrated in rat liver lysosomes (29) and yeast vacuoles (30), we asked whether SLC38A9.1 may have an important role in transmitting arginine levels to mTORC1. To this end, we examined how mTORC1 signaling responded to a range of arginine or leucine concentrations in HEK-293T cells in which we knocked out SLC38A9 using CRISPR-Cas9 genome editing (Fig. 5E). Activation of mTORC1 by arginine was strongly repressed at all arginine concentrations, whereas the response to leucine was only blunted, so that high leucine concentrations activated mTORC1 equally well in null and control cells (Fig. 5F).

Several properties of SLC38A9.1 are consistent with its functioning as an amino acid sensor for the mTORC1 pathway. Purified SLC38A9.1 transports and therefore directly interacts with amino acids. Overexpression of SLC38A9.1 or just its Ragulator-binding domain activates mTORC1 signaling even in the absence of amino acids. The activation of mTORC1 by amino acids, particularly arginine, is defective in cells lacking SLC38A9. Given these results and that arginine is highly enriched in lysosomes from at least one mammalian tissue (29), we propose that SLC38A9.1 is a strong candidate for being a lysosome-based arginine sensor for the mTORC1 pathway. To substantiate this possibility, it will be necessary to determine the actual concentrations of arginine and other amino acids in the lysosomal lumen and cytosol and compare them to the affinity of SLC38A9.1 for amino acids. If high arginine levels are a general feature of mammalian lysosomes, it could explain why SLC38A9.1 appears to have a relatively broad amino acid specificity; perhaps no other amino acid besides arginine is in the lysosomal lumen at levels that approach its Km.

The notion that proteins with sequence similarity to transporters function as both transporters and receptors (transceptors) is not unprecedented (31, 32). The transmembrane region of SLC38A9.1 might undergo a conformational change upon amino acid binding that is then transmitted to Ragulator through its N-terminal domain. What this domain does is unknown, but it could regulate Ragulator nucleotide exchange activity or access to the Rag GTPases by other components of the pathway. To support a role as a sensor, it will be necessary to show that amino acid binding regulates the biochemical function of SLC38A9.1.

Even if SLC38A9.1 is an amino acid sensor, additional sensors, even for arginine, are almost certain to exist, as we already know that amino acid–sensitive events exist upstream of Folliculin (15, 33) and GATOR1 (34), which, like Ragulator, also regulate the Rag GTPases. An attractive model is that distinct amino acid inputs to mTORC1 converge at the level of the Rag GTPases, with some initiating at the lysosome through proteins like SLC38A9.1 and others from cytosolic sensors that remain to be defined (Fig. 5G). Indeed, such a model would explain why the loss of SLC38A9.1 specifically affects arginine sensing but its overexpression makes mTORC1 signaling resistant to arginine or leucine starvation: Hyperactivation of the Rag GTPases through the deregulation of a single upstream regulator is likely sufficient to overcome the lack of other positive inputs. A similar situation may occur upon loss of GATOR1, which, like SLC38A9.1 overexpression, causes mTORC1 signaling to be resistant to total amino acid starvation (14).

Modulators of mTORC1 have clinical utility in disease states associated with or caused by mTORC1 deregulation. The allosteric mTOR inhibitor rapamycin is used in cancer treatment (35) and transplantation medicine (36). However, to date, there have been few reports on small molecules that activate mTORC1 by engaging known components of the pathway. The identification of SLC38A9.1—a protein that is a positive regulator of the mTORC1 pathway and has an amino acid binding site—provides an opportunity to develop small-molecule agonists of mTORC1 signaling. Such molecules should promote mTORC1-mediated protein synthesis and could have utility in combatting muscle atrophy secondary to disuse or injury. Lastly, a selective mTORC1 pathway inhibitor may have better clinical benefits than rapamycin, which in long-term use inhibits both mTORC1 and mTORC2 (37). SLC38A9.1 may be an appropriate target to achieve this.

Supplementary Materials

www.sciencemag.org/content/347/6218/188/suppl/DC1

Materials and Methods

Figs. S1 to S6

References

References and Notes

  1. Acknowledgments: We thank all members of the Sabatini Lab for helpful insights, E. Spooner for the mass spectrometric analyses, and G. Superti-Furga and M. Rebsamen for suggesting the use of the Sigma antibody to detect SLC38A9. This work was supported by grants from the NIH (R01 CA103866 and AI47389) and Department of Defense (W81XWH-07-0448) to D.M.S. and fellowship support from the NIH to Z.-Y.T. (F30 CA180754), to S.W. (T32 GM007753 and F31 AG044064), to L.C. (F31 CA180271), and to R.L.W. (T32 GM007753); a National Defense Science and Engineering Graduate Fellowship to G.A.W.; an NSF Graduate Research Fellowship to T.W.; an American Cancer Society–Ellison Foundation Postdoctoral Fellowship to W.C. (PF-13-356-01-TBE); a German Academic Exchange Service (DAAD Fellowship to C.S.; and support from the Howard Hughes Medical Institute to T.D.J., C.K., and J.P. D.M.S. and B.L.S. are investigators of the Howard Hughes Medical Institute.
View Abstract

Navigate This Article